(Q30423733)

21 June 2017

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection (English)

1 reference

21 June 2017

influenza A virus

1 reference

9

Karl-Josef Kallen

1 reference

21 June 2017

Benjamin Petsch

1

1 reference

21 June 2017

Margit Schnee

2

1 reference

21 June 2017

Annette B Vogel

3

1 reference

21 June 2017

Elke Lange

4

1 reference

21 June 2017

Bernd Hoffmann

5

1 reference

21 June 2017

Daniel Voss

6

1 reference

21 June 2017

Thomas Schlake

7

1 reference

21 June 2017

Andreas Thess

8

1 reference

21 June 2017

Lothar Stitz

10

1 reference

21 June 2017

Thomas Kramps

11

1 reference

21 June 2017

25 November 2012

1 reference

21 June 2017

1 reference

21 June 2017

30

1 reference

21 June 2017

12

1 reference

21 June 2017

1210-1216

1 reference

Influenza and the challenge for immunology

21 June 2017

1 reference

The influenza virus enigma

21 January 2018

1 reference

A distinct lineage of influenza A virus from bats

21 January 2018

1 reference

Vaccine manufacturing: challenges and solutions

21 January 2018

1 reference

Influenza vaccines for the future

21 January 2018

1 reference

Rapid-response vaccines--does DNA offer a solution?

21 January 2018

1 reference

Immunologic basis of vaccine vectors

21 January 2018

1 reference

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

21 January 2018

1 reference

Determinants of immunity to influenza infection in man

21 January 2018

1 reference

Vaccines: correlates of vaccine-induced immunity

21 January 2018

1 reference

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge

21 January 2018

1 reference

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

21 January 2018

1 reference

Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model

21 January 2018

1 reference

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

21 January 2018

1 reference

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

21 January 2018

1 reference

Comparative analysis of six European influenza vaccines

21 January 2018

1 reference

Translational research on vaccines: influenza as an example

21 January 2018

1 reference

Animal models in influenza vaccine testing.

21 January 2018

1 reference

Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection

21 January 2018

1 reference

Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs

21 January 2018

1 reference

Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes

21 January 2018

1 reference

Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.

21 January 2018

1 reference

Structure-based antigen design: a strategy for next generation vaccines

21 January 2018

1 reference

Intradermal electroporation of naked replicon RNA elicits strong immune responses

21 January 2018

1 reference

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

21 January 2018

1 reference

PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models

21 January 2018

1 reference

Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs.

21 January 2018

1 reference

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo

21 January 2018

1 reference

Vaccination with messenger RNA.

21 January 2018

1 reference

12 December 2020

New real-time reverse transcriptase polymerase chain reactions facilitate detection and differentiation of novel A/H1N1 influenza virus in porcine and human samples

1 reference

12 December 2020

Vaccination with messenger RNA (mRNA).

1 reference

12 December 2020

In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies

1 reference

12 December 2020

CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch

1 reference

12 December 2020

Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine

1 reference

12 December 2020

MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL

1 reference

12 December 2020

Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly

1 reference

12 December 2020

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

1 reference

12 December 2020

Developing mRNA-vaccine technologies

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NBT.2436

1 reference

21 June 2017

1 reference